192 related articles for article (PubMed ID: 32399434)
21. Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer.
Hur M; Park M; Moon HW; Choe WH; Lee CH
Ann Lab Med; 2022 Mar; 42(2):249-257. PubMed ID: 34635616
[TBL] [Abstract][Full Text] [Related]
22. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.
Liu J; Hu HH; Lee MH; Korenaga M; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; Mizokami M; Chen CJ; Yang HI
Sci Rep; 2017 Oct; 7(1):14352. PubMed ID: 29085039
[TBL] [Abstract][Full Text] [Related]
23. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.
Shirabe K; Bekki Y; Gantumur D; Araki K; Ishii N; Kuno A; Narimatsu H; Mizokami M
J Gastroenterol; 2018 Jul; 53(7):819-826. PubMed ID: 29318378
[TBL] [Abstract][Full Text] [Related]
24. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
25. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B.
Tsuji Y; Namisaki T; Kaji K; Takaya H; Nakanishi K; Sato S; Saikawa S; Sawada Y; Kitagawa K; Shimozato N; Kawaratani H; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Exp Ther Med; 2020 Aug; 20(2):985-995. PubMed ID: 32765655
[TBL] [Abstract][Full Text] [Related]
26. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.
Zhu MY; Chen PZ; Li J; Yu DM; Huang D; Zhu XJ; Han Y; Chen J; Huang W; Chen YY; Gong QM; Jiang JH; Zhang DH; Zhang Y; Zhang JM; Zhang XX
J Med Virol; 2018 Apr; 90(4):721-729. PubMed ID: 29247529
[TBL] [Abstract][Full Text] [Related]
27. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
28. Use of M2BPGi in HCC patients with TACE.
Tak KY; Jang B; Lee SK; Nam HC; Sung PS; Bae SH; Choi JY; Yoon SK; Jang JW
J Gastroenterol Hepatol; 2021 Oct; 36(10):2917-2924. PubMed ID: 34031909
[TBL] [Abstract][Full Text] [Related]
29. Novel biomarkers for the management of chronic hepatitis B.
Inoue T; Tanaka Y
Clin Mol Hepatol; 2020 Jul; 26(3):261-279. PubMed ID: 32536045
[TBL] [Abstract][Full Text] [Related]
30. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy.
Liu T; Sun Y; Zhou J; Yang F; Zou X; Wang L; Wu X; Chen Y; Piao H; Lu L; Jiang W; Xu Y; Feng B; Nan Y; Xie W; Chen G; Zheng H; Li H; Ding H; Liu H; Wang T; Ou X; Wu S; Kong Y; Wang P; Cong M; Zhang Y; You H; Jia J
J Med Virol; 2019 Aug; 91(8):1499-1509. PubMed ID: 30905065
[TBL] [Abstract][Full Text] [Related]
31. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Performance of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi), compared to Transient Elastography to Assess Liver Stiffness in Treatment Naïve Chronic Hepatitis C Patients.
Sulaiman AS; Hasan I; Lesmana CRA; Kurniawan J; Jasirwan COM; Nababan S; Kalista KF; Hanifa RS; Rachmani D; Gani RA
Acta Med Indones; 2022 Oct; 54(4):567-573. PubMed ID: 36624717
[TBL] [Abstract][Full Text] [Related]
33. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
34. Serum angiopoietin-2 levels predict regression of Mac-2 binding protein glycosylation isomer-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
Suzuki T; Matsuura K; Nagura Y; Ogawa S; Fujiwara K; Nojiri S; Watanabe T; Kataoka H; Tanaka Y
Hepatol Res; 2022 Nov; 52(11):919-927. PubMed ID: 35938598
[TBL] [Abstract][Full Text] [Related]
35. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma.
Nakai M; Morikawa K; Hosoda S; Yoshida S; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Ohara M; Sho T; Suda G; Ogawa K; Sakamoto N
World J Hepatol; 2022 Jul; 14(7):1480-1494. PubMed ID: 36158914
[TBL] [Abstract][Full Text] [Related]
36. [Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin].
Ishida H; Suetsugu A; Nakamura M; Tauchi R; Nakayama J; Katano Y; Shirakami Y; Furuta N; Ito H; Seishima M
Rinsho Byori; 2015 Aug; 63(8):901-6. PubMed ID: 26638424
[TBL] [Abstract][Full Text] [Related]
37. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.
Kikukawa K; Uchida-Kobayashi S; Tamori A; Yoshida K; Kotani K; Motoyama H; Kozuka R; Hagihara A; Fujii H; Morikawa H; Enomoto M; Murakami Y; Kawada N
Ann Hepatol; 2020; 19(4):367-372. PubMed ID: 32444247
[TBL] [Abstract][Full Text] [Related]
38. Association of Mac-2-binding protein glycosylation isomer level with nutritional status in chronic liver disease.
Eso Y; Takai A; Taura K; Takahashi K; Ueda Y; Marusawa H; Seno H
J Gastroenterol Hepatol; 2018 Feb; ():. PubMed ID: 29473206
[TBL] [Abstract][Full Text] [Related]
39. Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.
Harimoto N; Itoh S; Yamanaka T; Hagiwara K; Ishii N; Tsukagoshi M; Watanabe A; Araki K; Yoshizumi T; Shirabe K
Anticancer Res; 2022 Jan; 42(1):245-251. PubMed ID: 34969731
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
Xu H; Kong W; Liu L; Chi X; Wang X; Wu R; Gao X; Wang H; Qu L; Qi Y; Pan Y; Niu J
BMC Gastroenterol; 2017 May; 17(1):62. PubMed ID: 28486931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
